CAR20.19.22 T-cells is under clinical development by Miltenyi Biomedicine and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to GlobalData, Phase I drugs for Primary Mediastinal B-Cell Lymphoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CAR20.19.22 T-cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CAR20.19.22 T-cells overview
Gene-modified cell therapy is under investigation for the treatment of relapsed and refractory B-cell non-Hodgkin lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, Burkitt lymphoma, high-grade B-cell lymphoma, T-cell or histocyte rich B-cell lymphoma, primary mediastinal B-cell lymphoma, Epstein-Barr virus (EBV) diffuse large B-cell lymphoma. It is administered by intravenous route. The therapy comprises T-cells engineered to express chimeric antigen receptors (CAR) targeting cells expressing CD19, CD20 and CD22.
Miltenyi Biomedicine overview
Miltenyi Biomedicine, a subsidiary of Miltenyi Biotec GmbH, is a biopharmaceutical company that develops innovative cell and gene therapies and regenerative therapies for cancer treatments.
For a complete picture of CAR20.19.22 T-cells’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
